Background: CLEC18 is a novel C-type lectin not being characterized. Results: The amino acid residue in the C-type lectin-like domain of CLEC18 contribute to the differential glycan-binding ability. Conclusion: CLEC18 members are expressed in immune and non-immune cells, and preferentially bind to fucoidan, ␤-glucan, and galactan. Significance: The biochemical features, tissue distribution, and the glycan-binding specificity suggest that CLEC18 may contribute to host immunity against pathogens.
Dectin-1/CLEC7A and MDL1/CLEC5A) bind glycans in a Ca 2ϩ -independent manner (7, 8) . Moreover, proteins with less closely related CTLDs (such as CD69, CD72, KLRF1, of NK receptor family) do not appear to have carbohydrate-binding activity.
In the human genome, there are at least 57 CTLD-containing proteins divided into XVI groups (9) . Among these proteins, we are especially interested in group XV, the CLEC18 family, for following reasons: 1) the clec18 gene cluster contains three genes (clec18a, clec18b, and clec18c) located in human chromosome 16q22.1 (clec18a and clec18c), and 16q22.3 (clec18b). 2) Translation of clec18 cDNA predicted an N-linked polypeptide with a C-type lectin domain (CTLD) in the C terminus, and the SCP/TAPS (sperm-coating protein Tpx-1/Ag5/PR-1/Sc7) domain (also known as CAP (cysteine-rich secretory proteins, antigen 5, and pathogenesis-related 1) domain), which is a conserved tertiary ␣-␤-␣ structure stabilized by disulfide bonds. 3) Proteins of the SCP/TAPS/CAP domain have been proposed to play significant roles in host-pathogen interactions, reproduction, development, and immune function (10, 11) . 4) Several amino acid residues located in the CTLD and SCP/TAPS/CAP domains are distinct among the sequences retrieved from the NCBI database. However, the biochemical features of CLEC18 have not been tested yet.
In this study, we developed a real-time reverse transcription PCR-based platform with fluorescent hybridization probe to detect the presence of CLEC18 in various cell lines and primary cells, followed by direct sequencing cDNAs to confirm the PCR-based typing method. We found that CLEC18 mRNAs and proteins were detectable in various cell lines and human peripheral blood cells. Furthermore, CLEC18 encode N-linked glycoproteins located in endoplasmic reticulum (ER), Golgi apparatus, and endosomes. Moreover, amino acid residues Ser/ Arg 339 and Asp/Asn 421 located in the CTLD domain contribute to their differential glycan binding specificity. This observation suggests that CLEC18 may bind to various glycoconjugates with distinct affinity, and contribute to differential immune responses to glycoconjugates expressed on foreign antigens or altered self-antigen in ER, Golgi apparatus, and endosomes.
Experimental Procedures
Reverse Transcription and Cloning of CLEC18 by Polymerase Chain Reaction-Total RNA was extracted from cells using TRIzol according to the supplier's instructions, then subjected to reverse transcription using a RevertAid TM First Strand cDNA Synthesis Kit (Fermentas, Burlington ON, Canada) as template for PCR amplification. The CLEC18 cDNAs were amplified by denaturing for 60 s at 95°C, followed by 35 cycles of denaturation at 95°C for 10 s, annealing at 70°C for 45 s, and extension at 72°C for 80 s. The amplified cDNA fragment was ligated into yTA vector (RBC TA cloning vector kit) before being subcloned into pCMV-Tag4A vector (Stratagene) for expression in mammalian cells. To sequence the CLEC18 cDNA fragment extending from the SCP/TAPS domain to the CTLD domain (nucleotides 211 to 1304), a cDNA fragment was performed by a thermocycler (GeneAmp PCR System 9700, Applied Biosystem). The PCR program (denature/annealing/ extension) for amplification is as follows: 98°C, 10 s at 63°C, 30 s at 72°C, and 70 s for 30 cycles.
Determination of CLEC18 Alleles by Real-time PCR-The polymorphism of CLEC18A/B/C was determined by real-time PCR with hybridization probes (Roche Life Sciences). The position of primers are as shown in Fig. 2 , whereas the sequences of PCR primers and hybridization probes are listed in Table 1 . PCR was performed by a thermocycler (LightCycler480 II, Roche), followed by heat denaturation at 95°C for 60 s to determine CLEC18 polymorphism. The PCR program (denature/ annealing/extension) for amplification of the CTLD domain and is as follows: 95°C, 10 s at 66°C, 10 s at 72°C, and 10 s. The amplification cycles were followed by a melting cycle, in which DNA was denaturated at 95°C for 60 s using a rate of 4.4°C/s, cooled to 40°C for 60 s using a rate of 1.5°C/s and held for 30 s. The temperature was then raised to 75°C with a transition rate of 0.03°C/s. Fluorescence was continuously monitored during the melt.
Isolation of PBMC and Preparation of Human Macrophages and Dendritic Cells-Peripheral blood mononuclear cells (PBMCs) were isolated from the whole blood of healthy human donors by standard density-gradient centrifugation with Ficoll-Paque (Amersham Biosciences). To prepare primary macrophage, CD14 ϩ cells were purified from PBMCs by high-gradient magnetic sorting, using the VarioMACS technique with anti-CD14 microbeads (Miltenyi Biotec GmbH). Cells were then incubated in complete RPMI 1640 medium (Hyclone) supplemented with human M-CSF or GM-CSF/IL-4 for 7 days as described previously (12, 13) .
Western Blotting and Flow Cytometry Analysis-For Western blotting analysis, cells (1 ϫ 10 6 ) were lysed by RIPA buffer, followed by fractionation on 12% SDS-PAGE, before blotting onto PVDF membrane. Lysates were probed with anti-CLEC18 mAb (clone 3A9E6), followed by incubation with peroxidaseconjugated goat anti-mouse polyclonal antibody (Millpore AP181P) and Immobilon TM Western Chemiliminescent HRP Substrate (Millipore TM ). For flow cytometry analysis, cells were permeabilized with 0.1% saponin and incubated with the Alexa 647-conjugated anti-CLEC18 mAb (clone 3A9E6), then examined by flow cytometer (Verse TM , BD Biosciences). Data were analyzed by the FlowJow TM software.
Immunofluoresence Staining-Adherent cells were fixed with 4% paraformaldehyde for 1 h, then permeabilized with 0.5% Triton X-100 in PBS for 10 min before incubation in blocking buffer (10% BSA in PBS) for 60 min. Cells were then incubated with anti-CLEC18 mAb (40 g/ml in 3% BSA/PBS, room temperature for 1 h), anti-calreticulin (dilution range 1:100 in 3% BSA/PBS, 4°C, overnight), anti-GM130 (dilution range 1:150 in 3% BSA/PBS, 4°C, overnight), and anti-EEA1 (dilution range 1:100 in 3% BSA/PBS, 4°C, overnight), respectively. After washing, cells were incubated with Alexa 488-conjugated goat anti-mouse IgG (Jackson ImmunoResearch), TRITC-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch) for 1 h, and then Hoechst 33342 for 10 min. Samples were then mounted and observed under fluorescence confocal microscopy (Olympus FV10i). Alternatively, cells were incubated with MitoTracker Red (250 nM) or LysoTracker (100 nM) at 37°C for 1 h to observe their colocalization with CLEC18.
Immunoprecipitation and Mass Spectrometry Analysis-To
understand whether CLEC18A is a secretory protein, pCMV-Tag4A or pCMV-Tag4A-CLEC18A (2 g) was transfected into 293T cells (2 ϫ 10 5 ), respectively, followed by incubation at 37°C for 48 h before harvesting. Cell lysates or supernatant were incubated with anti-FLAG M2 affinity gel (Sigma, A2220) to pulldown CLEC18A. The immunoprecipitates were fractionated on a 12% SDS-PAGE, then probed with anti-CLEC18 mAb (clone 3A9E6), and further incubated with peroxidaseconjugated goat anti-mouse polyclonal antibody (Millpore AP181P) and Immobilon TM Western Chemiluminescent HRP Substrate (Millipore TM ) subsequently for detection. Alternatively, the immunoprecipitates were fractionated on 12% SDS-PAGE, then eluted from gel for mass spectrometry analysis. The eluted proteins were subjected to mass spectrometry analysis using the Thermo Finnigan LTQ FT Ultra High Perfor- mance Mass Spectrometer (Conquer scientific). The secretory CLEC18 in culture supernatants and sera was determined using a ELISA kit (CUSABIO Life Science).
Construction, Expression, and Purification of Fc-tagged Recombinant CLEC18.Fc Fusion Proteins-DNA fragments encoding the CTLD domain of CLEC18A/B/C were amplified by reverse transcriptase-PCR and subcloned into pcDNA3.1-hIgG 1 Fc (mut) vector to generate CLEC18A/A-1/B/C Fc fusion proteins, respectively. PCR primers are listed in Table 1 . The CLEC18B cDNA was generated by two steps of PCR to insert exon B using CLEC18A cDNA as template. The CLEC18.Fc fusion proteins were overexpressed by using the FreeStyle 293 Expression System (Invitrogen). Briefly, 3 ϫ 10 7 293F cells in 28 ml of culture medium were transfected with a mixture of 30 g of plasmid DNA and 60 l of 293fectin TM in a total of 2 ml of Opti-MEM I (Invitrogen). The culture supernatants were harvested at days 3 and 5, and the recombinant CLEC18.Fc fusion proteins were purified by Protein A column (GE Healthcare).
Polysaccharide Binding Assay-Samples of GLPS-F3 were weighed, dissolved, and diluted with 100 mM Tris buffer (pH 9.5) to give 20 g/ml as described previously (14) . Briefly, the GLPS-F3 was immobilized in the wells of 96-well plates (50 l/well, Corning) and incubated overnight at 4°C, followed by incubation with 200 l of blocking buffer (2% BSA/TBST) for 1 h at room temperature before washing with TBST (0.05% Tween 20/TBS) twice. Each well was incubated with 100 l of CLEC.Fc fusion protein (2 g/ml in 2 mM MgCl 2 , 2 mM CaCl 2 , 1% BSA/TBST) in the presence or absence of various glycans (Megazyme) as competitors for 1 h at room temperature. After washing with TBST, each well was incubated with 100 l of peroxidase-conjugated goat anti-human IgG Ab (Jackson Immu-noResearch) in 1% BSA/TBST (1:5000) at room temperature for 30 min, followed by addition of 100 l of tetramethylbenzidine substrate (BD Biosciences) for 20 min, and the reaction was stopped by 1 N H 2 SO 4 before subjecting to analysis by an ELISA reader (TECAN). Alternatively, fusion protein was incubated with zymosans at 4°C for 1 h and washed with PBS, followed by incubation with anti-hIgG1-FITC (1:200) at 4°C for 30 min and then analyzed using a Verse TM flow cytometer (BD Biosciences), and data were analyzed using FlowJow TM software.
Results

Chromosomal Location and Structure of clec18 Gene
Cluster-The clec18 gene cluster contains three loci: clec18a (16q22.1), clec18c (16q22.1), and clec18b (16q22.3). Both clec18a (Gene ID 348174) and clec18c (Gene ID 283971) comprise 12 exons, whereas a predicted extra exon (denoted as exon B) located between exons X and XI is found in clec18b (Gene ID 497190) ( Fig. 1, A and B ). clec18a (NM_182619.3) and clec18c (NM_173619.3) encode a 446-amino acid (aa) polypeptide, respectively, whereas clec18b is predicted to encode a 455-amino acid polypeptide with the extra nine amino acids (LVWL-SAAMG) derived from exon B (AGG CUG GUG UGG CUG AGU GCU GCC AUG GGGU) within the CTLD (Fig. 1C ). Compared with CLEC18A, CLEC18C is almost identical with CLEC18A except 2 amino acids (Thr 91 3 Ile 91 , Val 118 3 Als 118 ) located in SCP/TAPS/CAP domain (aa 45-190) and 1 amino acid (Asp 421 3 Asn 421 ) in WND motif located in FIGURE 1. Chromosomal location, structures, protein sequence, and alignment. A, the clelc18 gene family is located in human chromosomes 16q22.1 (clec18a and clec18c) and 16q22.3 (clec18b). B, the clec18a and clec18c comprise 12 exons, respectively, whereas an extra exon (exon B) is predicted in clec18b. C, clec18a and clec18c encode a polypeptide of 446 aa, respectively, whereas clec18b is predicted to encode a polypeptide of 455 aa due to the extra 9 amino acid residues translated from the exon B in clec18b. The polymorphic amino acid residues among members of the CLEC18 family are indicated. D, multiple sequence alignment of CTLD of human CLEC18 and other species. Only the human genome contains three genes (clec18a, clec18b, and clec18c), whereas other species only contain one gene (clec18a) in the genome. Only human and chimpanzee CLEC18 are predicted to contain exon B with 9-inserted amino acid residues (LVWLSAAMG) in the CTLD. *, the polymorphic amino acid residues (339 and 421) found in human CLEC18 family.
CTLD. In addition, four amino acid residues (Thr 91 3 Ile 91 , Val 118 3 Ala 118 , Ala 173 3 Thr 173 , Arg 185 3 Gly 185 ) located in the SCP/TAPS domain (aa 45-190), and one amino acid residue (Val 196 3 Ile 196 ) located between the SCP/TAPS/ CAP domain and EGF regions (aa 232-292) were noted among CLEC18A, CLEC18B, and CLEC18C. Moreover, CLEC18A-1 (AAI41809.1), which contains three distinct amino acid residues from CLEC18A (Val 118 3 Ala 118 and Thr 151 3 Met 151 in SCP/TAPS/CAP domain and Ser 339 3 Arg 339 in CTLD) was found in the human genome database (Fig. 1C ).
Alignment of human CLEC18 with CLEC18 of other species shows that CLEC18 is highly conserved in CTLD, but the predicted 9-amino acid insertion is only found in human CLEC18B and chimpanzee CLEC18 (Fig. 1D ). The typical motifs of CTLDs, such as "WIGL" (aa 370 -373), "QPD" (aa 399 -401), and "WND" (aa 419 -421), are found in both human and nonhuman CLEC18. It is interesting to note that the "Asp 421/430 " located in the "WND" motif of CLEC18A/B is replaced with "Asn 421 " in human CLEC18C. Moreover, the basic amino acid residues Arg 322 and Arg 329 found in human and chimpanzee are replaced with Gly 322 and Gly/Glu 329 in non-primates. Furthermore, the aliphatic amino acid residues Ile 360 , Ala 385 , and His 403 found in human and chimpanzee are replaced with Thr/ Met/Ser 369 , Thr/Asp 385 , and Gln 403 in non-primate CLEC18.
Detection of CLEC18 Alleles by Real-time Reverse Transcription-PCR (RT-PCR)-Due to the highly conserved cDNA sequences among CLEC18, nucleotide residues (Cys/Ala 1017 and Gly/Ala 1261 ) located in CTLD were used to discriminate each member of the CLEC18 family by hybridization probebased real-time RT-PCR assay. In addition, a probe hybridizing the extra exon B was used to detect CLEC18B (Fig. 2) . We found that CLEC18A mRNA was expressed in almost all the cell lines tested, whereas CLEC18A-1 was detectable in CHME3, A549, and the human peripheral blood cells (PBCs) of three donors. CLEC18C mRNA was also detectable in some cell lines, but was less prevalent than CLEC18A. However, we cannot detect CLEC18B mRNA in all the cell lines by PCR using the probe hybridizing the exon B (Table 2, part A). We further investigated the expression of CLEC18 mRNAs in human PBMCs from healthy donors. Although CLEC18A mRNAs were detectable in all the samples tested, the expression of CLEC18A-1 and CLEC18C was less prevalent than CLEC18A. However, CLEC18B mRNA is not detectable in all the samples tested ( Table 2 , part B).
We further examined the presence of other CLEC18A/B/C alleles in cell lines and human PBCs by sequencing the CLEC18 cDNAs amplified by RT-PCR. Interestingly, two discrepancies with the reference sequences were found. 1) The dominant amino acid residues located in the SCP/TAPS/CAP domain (Table 3 , B and C). This observation suggests that the putative exon B is absent in human CLEC18B, and multiple alleles are present in all the members of CLEC18 family.
CLEC18 Are N-linked Glycoproteins Detectable in Cell Lysates and Culture Supernatant-We further investigated the expression of CLEC18 by Western blotting and flow cytometry. We found that anti-CLEC18 mAb (clone 3A9E6) detects a specific band migrating at 50 kDa in 293T cells transfected with CLEC18A and CLEC18C cDNAs, respectively (Fig. 3A) . The peptide was eluted for mass spectrometry analysis, and the sequences of peptides matched CLEC18 perfectly (Fig. 3B ). Because two potential glycosylation sites (Asn 144 and Asn 243 ) were predicted when analyzing CLEC18 by Vector NTI software (version 11), we asked whether CLEC18 are N-linked glycosylated proteins. To address this question, FLAG-tagged CLEC18A-transfected 293T cells were incubated with tunicamycin to observe the change of M r of CLEC18. We found the CLEC18A polypeptide migrated from 50 to 45 kDa in a timedependent manner when probed with anti-FLAG mAb (Fig.  3C) , and a similar result was observed after peptide:N-glycosidase F treatment (Fig. 3D ). This observation indicates that CLEC18A is a 50-kDa N-linked glycoprotein.
We further examined its expression in human PBCs and CD14 ϩ -derived macrophages and dendritic cells by flow cytometry and Western blotting. To address this question, CD14 ϩ -derived dendritic cells were incubated with GM-CSF ϩ IL-4 (25 ϩ 20 ng/ml), GM-CSF (10 ng/ml), and M-CSF (10 ng/ml) for 7 days, respectively, to differentiate into dendritic cells (DCs), GM-macrophages (GM-M), and M-macrophages (M-M). We found that CLEC18 are abundantly expressed in human PBCs, including T cells (CD3 ϩ ), B cells (CD19 ϩ ), granulocytes (CD66b ϩ ), and monocytes (CD14 ϩ ) (Fig. 4A ). Compared with monocytes, CLEC18 were further up-regulated in monocyte-derived DCs, GM-M, and M-M (Fig. 4B, upper) , and the protein expression level in accord with CLEC18 mRNA levels was determined by real-time PCR (Fig. 4B, lower) . This observation suggested the CLEC18 expression is up-regulated by cytokines. However, the expression of CLEC18 was low and barely detectable in several hematopoietic cell lines ( Fig. 4C ) and non-hematopoietic cell lines (data not shown).
It has been shown that members of protein with the SCP/ CAP domain are soluble proteins (11, 15) , thus we asked whether CLEC18 are secretory proteins. To address this question, culture supernatants of pCMV-Flag-CLEC18A-transfected 293T cells were incubated with anti-FLAG mAb to pulldown soluble CLEC18A, followed by Western blot analysis using anti-CLEC18 mAb (clone 3A9E6). We found that CLEC18A is not only detectable in culture supernatant of pCMV-Flag-CLEC18A-transfected 293T cells (Fig. 4D ), but also in the culture supernatant of DCs, GM-M, and M-M (upper, Fig. 4E ), as well as in human sera (Fig. 4E, lower) as determined by ELISA. This observation suggests that CLEC18A is a secretory protein.
Subcellular Localization of CLEC18 -Because CLEC18 were detectable in cell lysates, we further investigated its subcellular localization. To address this question, human CD14 ϩ -derived M-M was incubated with anti-CLEC18A mAb, followed by incubation with Alexa 488-conjugated goat anti-mouse mAb.
To determine its subcellular localization, M-M was also coincubated with anti-GM 130 mAb (rabbit), anti-calreticulin mAb (rabbit), and anti-EEA1 mAb (rabbit), respectively, followed by incubation with TRITC-conjugated goat anti-rabbit mAb. We found that CLEC18 were co-localized with GM 130 (marker for Golgi apparatus), calreticulin (marker for endoplasmic reticulum), and EEA1 (marker for early endosome), but not with MitoTracker (mitochondria dye) or LysoTracker (lysosome dye) under the same conditions (Fig. 5 ). This observation suggests that CLEC18 are located in the ER, Golgi apparatus, and early endosomes.
Tissue Distribution of CLEC18 -We further used a human tissue array to detect the expression of CLEC18 by immunohistochemistry staining. We found that CLEC18 were expressed in human spleen (leukocytes), brain (microglia), liver (hepatocytes), gall bladder (epithelial cells), fallopian tube (epithelial cells), and testis (epithelial cells) (Fig. 6 ). This observation suggests that CLEC18 are not only expressed in hematopoietic lineages, but also expressed in epithelial and parenchymal cells.
Differential Glycan Binding Ability of CLEC18A, CLEC18A-1, and CLEC18C-We further investigated the role of amino acid residues Ser/Arg 339 and Asp/Asn 421 in CTLD of the CLEC18 family in the binding ability to glycans. To address this question, Ser 339 and Asp 421 were located in CTLD of CLEC18A (Ser 339 , Asp 421 ) were mutated into Arg 339 and Asn 421 , respectively, to generate CLEC18A-1 (Arg 339 , Asp 421 ) and CLEC18C (Ser 339 , Asn 421 ). The CTLD domain of CLEC18A and mutants was ligated with pcDNA3.1-hIgG 1 Fc (mut) to obtain pCLEC18A.Fc, pCLEC18A-1.Fc, and pCLEC18C.Fc, respectively, followed by transfection to 293F cells to obtain recombi- . Arrow, CLEC18. D, the 293T cells were transfected with vector or pCMV-Tag4A-CLEC18A for 48 h, and the supernatant or lysates were incubated with anti-FLAG mAb to pulldown CLEC18, followed by Western blot analysis. E, detection of secretory CLEC18 in culture media and human sera. Culture supernatants (upper) of monocyte, dendritic cells, and macrophages and human sera (lower) were determined by ELISA (CUSABIO Life Science). ND, not determined. nant fusion proteins as described previously (8, 14, 16) . To understand whether the presence of exon B (encoding "LVWL-SAAMG") affects the glycan-binding ability, we inserted the 9 amino acids into CLEC18A CTLD to generate pCLEC18B.Fc. The recombinant CLEC18A.Fc, CLEC18A-1.Fc, and CLEC18C.Fc fusion proteins were then used to hybridize with the synthetic oligosaccharide glycan arrays from CFG (Consortium for Functional Glycomics, slides 14508, 14506, and14507; PMT70 version 5.0 Alexa 48810/20/11 HJ). However, the fusion proteins did not bind any glycans spotted on the glass slides, because the signals are weak (relative fluorescence units Ͻ 10,000) and the coefficient variation is high (CV Ͼ 50%) (supplemental Data 1, A-C) . Thus, we further tested their binding ability to F3 polysaccharides isolated from medicinal fungi Ganoderma lucidum (GLPS-F3), followed by a glycan competition assay to determine binding specificity as described previously (14, 16) .
It has been shown that GLPS-F3 contains abundant polysaccharides comprising glucose, mannose, fucose, galactose, xylose, GlcNAc, and rhamnose (17) , and GLPS-F3 is able to interact with several C-type lectins and Toll-like receptors (14) . Thus, we examined the interaction between CLEC18 and GLPS-F3 using Dectin1.Fc and DC-SIGN.Fc as controls. Similar to Dectin1.Fc and DC-SIGN.Fc, we found that CLEC18A.Fc and CLEC18C.Fc also bound to F3 polysaccharides, whereas the Ser 339 3 Arg 339 mutation (CLEC18A-1.Fc) and insertion of the 9-amino acid LVWLSAAMG in the CTLD domain (CLEC18B.Fc) abolished their binding ability to GLPS-F3 (Fig.  7A ). Interestingly, EDTA was unable to abolish binding of Dectin1.Fc, CLEC18A.Fc, and CLEC18C.Fc to F3 polysaccharide, although EDTA inhibited DC-SIGN.Fc binding to F3 efficiently under the same condition (Fig. 7A) . A similar observation was observed when incubating fusion proteins with zymosans ( Fig. 7B ) and house dust mite (Fig. 7C ). Because Dectin-1.Fc binding to ␤-glucans is independent of Ca 2ϩ (7) , this observation suggests that CLEC18 binding to the F3 polysaccharides and zymosans is also Ca 2ϩ -independent, and amino acid residue Ser 339 is critical for binding to polysaccharides.
We further determined the glycan-binding specificity of CLEC18A and CLEC18C by a sugar competition assay (14) using monosaccharides ( Fig. 8A) and polysaccharides (Fig. 8B) as competitors. Even though mannose and fucose competed with DC-SIGN.Fc binding to GLPS-F3 in a dose-dependent manner (Fig. 8A, left) , none of the monosaccharides (GlcNAc, galactose, mannose, and fucose) were able to inhibit CLEC18A.Fc (Fig. 8A, middle) and CLEC18C.Fc (Fig. 8A, right  most) binding to GLPS-F3 under the same condition. We further used polysaccharides to replace monosaccharides for competition assays. Among the 15 polysaccharides tested (Table 4 and Fig. 7D ), fucoidan (sulfated fucose), laminarin (␤-1,3linked glucan with ␤-1,6-linked side chain), and galactan (␤4-GlcNac) could inhibit CLEC18A.Fc and CLEC18C.Fc binding to GLPS-F3 ( Fig. 8B, lower) . Interestingly, pachyman (␤-1,3linked glucan) were less efficient than laminarin (␤-1,3-linked glucan with ␤-1,6-linked side chain) to inhibit CLEC18A/C binding to GLPS-F3, although pachyman was more efficient than laminarin to inhibit Dectin-1 binding to GLPS-F3 ( Fig. 8B,  upper right) . In contrast, mannan was unable to inhibit CLEC18A/C binding to GLPS-F3, even though mannan efficiently inhibited DC-SIGN binding to GLPS-F3 ( Fig. 8B, upper  left) . Therefore, the CTLD domain of CLEC18A/C preferred binding to sulfated fucose, ␤-glucan, and galactan.
Discussion
Several unusual features of CLEC18 are also noted in this study. 1) It is surprising to find that CLEC18A/C bind GLPS-F3 in a Ca 2ϩ -independent manner, even though the typical WND domain was present in CLEC18A. 2) Presence of the Gln 399 -Pro 400 -Asp 401 tripeptide motif in CLEC18 CTLD predicts binding specificity to galactose and GalNAc. However, sugar competition assays showed that CLEC18A and CLEC18C displayed diverse binding specificity to various glycans, including galactan (␤4-GlcNac), fucoidan, and ␤-glucan. In addition, amino acid residue Asp 421 /Asn 421 has a mild effect on F3 binding, because laminarin and galactan have a better inhibitory effect to CLEC18C.Fc (Asn 421 ) than CLEC18A.Fc (Asp 421 ) in higher concentrations (100 g/ml). Thus, amino acid residue Ser/ Arg 339 has a decisive role to determine CLEC18 binding to GLPS-F3, whereas Asp/Asn 421 only has a mild effect to influence their binding to laminarin and galactan, and fucoidan (Fig.  8B ). In addition, the stronger inhibitory effects of laminarin (␤-1,3-linked glucan with ␤-1,6-linked side chain) than pachyman (␤-1,3-linked glucan) suggests that CLEC18A.Fc and CLEC18C.Fc seem to be preferentially binding to the ␤-1,6-linked side chain of ␤-glucans. 3) CLEC18 are not only located in the ER, Golgi apparatus, and endosome of the primary macrophage ( Fig. 5 ), but also detectable in the culture supernatant of 293T cells overexpressing CLEC18 (Fig. 4D ). However, overexpression often results in a non-physiological cell response, thus the subcellular distribution of CLEC18 and the presence of soluble CLEC18 under physiological conditions needs to be verified further.
In contrast to L-type lectins calreticulin/calnextins, which are ER membrane proteins acting as chaperons to bind GlcM 3 (Glc-␣133-Man-␣132-Man-␣132-Man) of Glc 1 FIGURE 7 . Determination of the sugar binding ability of CLEC18. A, polysaccharides isolated from the G. lucidum F3 fraction (GLPS-F3) were immobilized on an ELISA plate (20 g/ml), followed by incubation with Dectin-1.Fc, DC-SIGN.Fc, and CLEC18.Fc family proteins (2 g/ml), in the presence or absence of EDTA (5 mM). B, incubation of Dectin-1.Fc or CLEC18.Fc family proteins (10 g/ml) with zymosan (10 mg/ml, Sigma), in the presence or absence of EDTA. The numbers represent the mean fluorescence intensity. C, house dust mite (5 g/ml) were immobilized on a ELISA plate, followed by incubation with Dectin-1.Fc, DC-SIGN.Fc, and CLEC18.Fc family proteins (2 g/ml), in the presence or absence of EDTA (5 mM). D, interaction of CLEC18A/C with various polysaccharides (as shown in Table 4 ) by ELISA. N, noncompetitor.
Man 9 GlcNAc 2 attached to glycoproteins in the ER for N-linked glycosylation (18) , no significant binding to GlcM 3 or other glycans spotted on CFG glycan arrays was noted by recombinant CLEC18A/A-1/C fusion proteins (supplemental Fig. S1 , 92928 -247015 M A-C). Furthermore, CLEC18A.Fc and CLEC18C.Fc bind GLPS-F3 ( Fig. 7A ) and zymosans (Fig. 7B ) in a Ca 2ϩ -independent manner, and display diverse binding specificity to various glycans ( Fig. 7D and Table 4 ). Thus, CLEC18 does not seem to be involved in N-linked glycosylation in the ER and Golgi apparatus. This argument is further supported by the histochemical staining that CLEC18 are not ubiquitously expressed in all the cell types ( Fig. 6 ). Because CLEC18 does not contain the "H/KDEL" tetrapeptide motif critical for ER retention, we asked whether CLEC18 was retained in ER via association with other proteins. To address this question, FLAG-tagged CLEC18A was precipitated from CLEC18A-transfected 293T cells by anti-FLAG mAb, and the immunoprecipitates were subjected to mass spectrometry analysis. We found that CLEC18A was coimmunoprecipitated with the ER protein Grp78/Bip (data not shown). However, we were unable to co-precipitate CLEC18A and Grp78/Bip from cells with or without stress (data not shown), thus how CLEC18 were retained in the ER and Golgi apparatus needs to be further investigated in the future.
It has been shown that proteins with the SCP/TAPS/CAP domain, such as the pathogen-related yeast proteins and human CAP family member CRISP2, are necessary and sufficient for lipid export and sterol binding (15, 19) . Because CLEC18 contains both CTLD and SCP/TAPS/CAP domains, it is reasonable to speculate that CLEC18 may bind glycolipids and are involved in the transport of glycolipids. The distinct amino acid residues in the SCP/TAPS/CAP domain may also contribute to binding specificity and affinity of CLEC18 to glycolipids and other glycoconjugates. Furthermore, it has been speculated that the plant pathogenesis-related 1 protein, a hostdefense protein with the SCP/TAPS/CAP domain, may serve to inhibit pathogen proliferation by extracting sterols from the pathogen membrane (15) . Therefore, CLEC18 may extract the sterol component of pathogen assembly in the ER and Golgi apparatus (such as members of flaviviruses) and attenuate their infectivity. This speculation is supported by the fact that CLEC18 are up-regulated in human macrophages and dendritic cells (Fig. 4B) , which are the major targets of flaviviruses. Furthermore, the Golgi-associated plant pathogenesis related protein 1 (GAPR-1), a mammalian protein with SCP/TAPS/ CAP domain, is shown to interact with acidic phospholipids and inhibits A␤ aggregation (20) .
The above evidence suggests that CLEC18 may be involved in recognition and transportation of glycoconjugates, and it would be interesting to investigate how the polymorphic amino acid residues in SCP/TAPS/CAP and CTLD domains determine CLEC18 binding specificity and affinity to various glycoconjugates in the future. 
